Hanx Biopharmaceuticals, Ltd. Showcases Five Innovative Cancer Therapies at 2025 AACR Annual Meeting

Hanx Biopharmaceuticals, Ltd. Showcases Five Innovative Cancer Therapies at 2025 AACR Annual Meeting

CHICAGO, May 7, 2025 /PRNewswire/ -- Hanx Biopharmaceuticals Ltd. (HanxBio), a clinical-stage biotechnology company pioneering next-generation immunotherapies, highlighted its expanding oncology and autoimmune disease pipeline with five research...

Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.

Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.

AJICAP® Antibody-Drug Conjugate Manufacturing Technology Contributes to Enhanced Efficacy of Antibody Drugs TOKYO, May 7, 2025 /PRNewswire/ -- Ajinomoto Co., Inc. (President: Shigeo Nakamura, Headquarters: Chuo-ku, Tokyo, hereinafter referred to as...

Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema

Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema

SAN FRANCISCO and SUZHOU, China, May 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...

Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)

Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)

First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used for Completion of All Activities to Support Planned NDA Submission in the Second Half of 2025, Along with Plans for...

TTEC Expands India Operations with New Mohali Customer Experience Center, Adding 400 New Jobs

TTEC Expands India Operations with New Mohali Customer Experience Center, Adding 400 New Jobs

AUSTIN, Texas and MOHALI, India, May 6, 2025 /PRNewswire/ -- TTEC Holdings, Inc. (NASDAQ: TTEC), a leading global customer experience (CX) technology and services innovator, today announced the expansion of its India operations with a new customer...

Sycomp Expands Locations and Warehouse Capacity to Support Global Customers

Sycomp Expands Locations and Warehouse Capacity to Support Global Customers

FOSTER CITY, Calif., May 6, 2025 /PRNewswire/ -- Sycomp A Technology Company, Inc., announced today the expansion of its global operations with new locations in Germany, Iceland, Nigeria, Saudi Arabia, Spain, Sri Lanka and Uruguay. Concurrently, the...

China Automotive Systems to Announce Unaudited 2025 First Quarter Financial Results on May 14, 2025

China Automotive Systems to Announce Unaudited 2025 First Quarter Financial Results on May 14, 2025

WUHAN, China, May 6, 2025 /PRNewswire/ -- China Automotive Systems, Inc. (Nasdaq: CAAS) ("CAAS" or the "Company"), a leading power steering components and systems supplier in China, today announced that it will issue unaudited financial results for...

PONY AI Inc. and Uber Announce Strategic Partnership to Advance Autonomous Mobility

PONY AI Inc. and Uber Announce Strategic Partnership to Advance Autonomous Mobility

GUANGZHOU, China and SAN FRANCISCO, May 6, 2025 /PRNewswire/ -- Pony AI Inc. ("Pony.ai") (Nasdaq: PONY), a global leader in achieving large-scale commercialization of autonomous mobility, and Uber Technologies, Inc. ("Uber") (NYSE: UBER), today...

Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025

Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025

SAN FRANCISCO and SUZHOU, China, May 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...

Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics

Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics

PHILADELPHIA, May 2, 2025 /PRNewswire/ -- Darnatein, a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), a biotechnology company advancing design-augmented biologics, announced today that it will present scientific data at the 14th International Bone...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 32
  • menu
    menu